论文部分内容阅读
目的:探讨尿激酶与阿替普酶治疗急性心肌梗死患者的临床疗效。方法:选取广州医科大学附属第三医院和广州市荔湾区中医医院于2014年3月至2016年6月收集的90例急性心肌梗死患者,按照双盲法分为两组。对照组45例患者采用尿激酶治疗,观察组45例采用阿替普酶治疗。治疗结束后,比较两组患者临床有效率,并就两组患者不良反应发生情况展开分析。同时,观察两组患者治疗前后心功能各项指标比较情况。结果:观察组和对照组临床有效率分别为91.11%、80%,差异具有统计学意义(P<0.05)。治疗过程中,观察组患者总计出现4例不良反应,对照组总计发生9例不良反应,两组比较差异具有统计学意义(P<0.05)。治疗结束后,两组患者心功能各项指标均较治疗前显著改善,且观察组显著优于对照组,差异具有统计学意义(P<0.05)。结论:针对急性心肌梗死患者,给予阿替普酶治疗效果更好,不但不良反应少,还可改善患者心功能。
Objective: To investigate the clinical efficacy of urokinase and alteplase in patients with acute myocardial infarction. Methods: Ninety patients with acute myocardial infarction collected from the Third Affiliated Hospital of Guangzhou Medical University and the Liwan District Hospital of Traditional Chinese Medicine from March 2014 to June 2016 were divided into two groups according to the double-blind method. 45 patients in the control group were treated with urokinase and 45 in the observation group were treated with alteplase. After treatment, the clinical efficacy of the two groups were compared, and the incidence of adverse reactions in both groups were analyzed. At the same time, the two groups of patients before and after treatment of cardiac function comparison of various indicators. Results: The clinical effective rates in the observation group and the control group were 91.11% and 80% respectively, with statistical significance (P <0.05). During the course of treatment, there were 4 adverse reactions in the observation group and 9 adverse reactions in the control group. The difference between the two groups was statistically significant (P <0.05). After treatment, the indexes of cardiac function in both groups were significantly improved compared with before treatment, and the observation group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion: For patients with acute myocardial infarction, given alteplase treatment effect is better, not only less adverse reactions, but also improve the patient’s cardiac function.